预成形钛网修复眼眶内、下壁联合骨折的临床观察

目的 探讨预成形钛网经单一下睑缘切口治疗眼眶内、下壁联合骨折的临床效果及其安全性.方法 回顾性总结2008年1月至2009年6月收治的18例眼眶内、下壁联合骨折患者.术前眼球内陷(与健眼差值-3～-6mm)18例,眼肌运动受限8例,复视6例.所有患者均经下睑缘皮肤切口行眶壁骨折整复术,植入预成形钛网修复骨折缺损.术后随访6～12个月,平均8.9个月.术前、术后行眼眶CT水平及冠状位扫描并进行比较.结果 眼球内陷矫正(与健眼突出度差值≤±1.5mm)14例,眼球内陷改善(与健眼差值-2～-3mm)4例;眼球运动受限完全矫正5例,明显改善3例;5例患者复视完全消失,1例患者复视有所改善.18例患者手术前后视力无明显改变,未出现溢泪、钛网感染、排异和移位等并发症.CT显示钛网重建骨壁位置与健侧骨壁对称.结论 应用预成形钛网治疗眼眶内、下壁联合骨折安全、有效,且钛网重建骨壁位置更加精确、稳定.     

眼眶减压术治疗30例恶性突眼的疗效观察

目的 评价眼眶减压术治疗严重恶性突眼患者的疗效。方法 采用眼眶减压术治疗30例(34只眼)恶性突眼患者,其中二壁减压术22,只眼,三壁减压术12只眼。术后随访3个月至9年,平均4．5年。观察恶性突眼患者术后视力、眼球突出度、眼球活动度及外观情况。结果 34只眼术后眼睑均能完全闭合。视力：提高25只眼,无改变5只眼,下降4只眼。眼球突出度：二壁减压术后(18．5mm)较术前(22．3mm)明显减小,三壁减压术后(18．6mm)较术前(25．7mm)明显减小。结论 眼眶减压术是治疗严重恶性突眼的有效方法。     

改良三壁眶减压术治疗重症甲状腺相关性眼病的疗效观察

目的观察改良三壁眶减压术治疗重症甲状腺相关性眼病的效果。方法对我院收治的3例(6眼)经内科治疗无效的重症甲状腺相关性眼病患者实施改良三壁眶减压术,观察患者术后视力、眼球突出度及外观情况。结果术后4眼视力轻度提高,2眼保持不变;眼球后退5.3～12.6mm,平均9.5mm;睑裂闭合不全者术后均闭合良好,外观满意;1眼出现少量眶内血肿,治疗后吸收;4眼出现双眼复视,均于1个月内消失;术后CT显示眼眶减压良好。结论改良三壁眶减压术可有效扩大眼眶容积,降低眶内压,还纳眼球,减少眼球突出,改善外观,对内科保守治疗、常规眶减压术无效的重症甲状腺相关性眼病患者安全有效。     

甲状腺相关眼病眼眶减压术的疗效分析

目的：探讨眼眶减压术在甲状腺相关眼病中治疗的价值。方法：回顾性分析中山眼科中心1993－2000年27例（30只眼）经全身和眼部临床检查（视力、视野或视觉诱发电位等）确诊为甲状腺相关眼病患者采用眼眶减压术（一壁、二壁及三壁减压）治疗的临床资料,观察其手术前和手术后患者视力、眼球突出度及眼球运动的变化。术后随访2个月至7年,平均13．7个月。结果：视力：19只眼（63．3％）明显提高;4只眼（13．3％）轻度提高,视力均保持在0．2－0．8;4只眼（13．3％）视力无变化,其中3只眼（10．0％）视力下降。24只眼（80．0％）眼球突出后退≥3．0mm,28只眼（93．3％）眼球突出后退≥2．0mm,平均眼球突出后退3．6mm。结论：眼眶减压术可提高甲状腺相关眼病患者的视力,减轻其眼球突出度。     

眶脂肪脱出术治疗甲状腺相关眼病

目的 :回顾和评价眶脂肪脱出术治疗甲状腺相关眼病眼球突出的疗效。方法 :经眼睑或结膜切口入路 ,切除肌肉圆锥内、外的脂肪 ,达到降低眶压 ,减少眼球突出度的目的。结果 :切除眶脂肪 1 5～ 11ml,平均 3 9ml,矫正眼球突出度 2～ 6mm ,平均 3 1mm。该治疗副作用很少 ,不影响视力及眼球运动 ,与提上睑肌延长术联合效果更佳。结论 :眶脂肪脱出术可以缓解眼球突出 ,是治疗甲状腺相关眼病性突眼的有效方法     

眼眶二壁减压术治疗12例Graves眼病 压迫性视神经病变

目的评价眼眶减压术治疗压迫性视神经病变的疗效。方法对12例患者14只Graves眼病合并压迫性视神经病变眼施行了二壁眶减压术,减压骨壁尽量靠近眶尖。结果14只眼术后均能完全闭合。视力提高11只眼,基本不变2只眼,下降1只眼。眼球突度平均减少4.0 mm。结论二壁眶减压术是治疗Graves眼病压迫性视神经病变的有效方法。(中华眼底病杂志,2001,17:303-304)     

眼眶平衡减压术治疗甲状腺相关眼病

目的 探讨平衡眼眶减压术治疗甲状腺相关眼病的疗效和手术方法。方法 采用内外壁眼眶减压术治疗20例35眼甲状腺相关眼病患者。术后随访平均14个月。观察术后视力、眼球突出度和眼球运动等情况。结果 20例35眼中除1例行眶外壁减压外，其余均行内外壁平衡眼眶减压术。眼球突出度缓解3～11mm，其中3～4mm者5眼，5～9mm者28眼，10～11mm者2眼，平均6．32mm。视力从术前数指提高至0．1者6眼，提高2行以上者8眼，无变化21眼。术后眼球运动明显好转者9眼，运动障碍加重2眼。无视力丧失及术后感染。结论 平衡眼眶减压术是治疗甲状腺相关眼病的有效方法。     

经冠状入路眼眶减压术26例

目的探讨经冠状入路眼眶减压术(coronal surgical approach to orbital decompression，CSAD)的临床疗效。方法选择双眼甲状腺相关眼病(thyroid associated Ophthalmopathy，TAO)患者26例(52眼)，行CSAD手术，其中二壁减压20例，三壁减压6例。结果手术前平均睑裂宽度14．5mm，手术后11．7mm；术前平均眼球突出度23mm；术后平均眼球突出16．8mm。平均后退6．2mm，术后视力提高18例(36眼)无变化7例(14眼)减退1例(2眼)；术后复视改善17例，无变化6例，复视症状加重3例。结论CSAD具有减压效果明显，并发症少，术后眼部无瘢痕等优点。     

改良结膜入路眼眶内下壁减压术治疗轻中度甲状腺相关眼病的临床效果

目的　评价改良结膜入路眼眶内下壁减压术治疗轻中度甲状腺相关眼病的疗效。方法　回顾性分析2017年1月至2018年8月在云南省第二人民医院行改良结膜入路眼眶内下壁减压术治疗的10例（11眼）轻中度甲状腺相关眼病患者。所有患者在术前均给予眼眶水平位、冠状位和矢状位CT检查,测量视力、眼球突出度、复视情况,检查眼外观进行眼前段照相等。将手术前、后眼球突出度,视力以及复视的改善情况作为效果评价指标,对相关数据进行统计和分析。结果　本组11眼术前眼球突出度为（18.94±1.40）mm,术后（15.22±1.46）mm;术后与术前比较,眼球突出度降低（3.72±0.64）mm,差异有统计学意义（t=18.379,P＜0.001）。术前视力为 0.53±0.29,术后为0.62±0.32;术后与术前比较,视力提高0.08±0.10,差异有统计学意义（t=-2.733,P=0.021）。术前复视2例;术后新发生复视2例,均为轻度复视。术前已存在复视的患者,术后复视程度无加重。结论　改良结膜入路眼眶内下壁减压术能有效改善甲状腺相关眼病患者的眼球突出度与视力,术后复视发生概率低,手术切口隐蔽美观,是一种可靠且有效的眶减压术式。     

眶脂肪切除联合提上睑肌延长术治疗甲状腺相关眼病

目的探讨眶脂肪切除联合提上睑肌延长术治疗甲状腺相关眼病的疗效。方法14例(21眼)经眼睑和结膜切口入路,切除肌肉圆锥内、外的脂肪联合提上睑肌延长术,达到降低眶压、减少眼球突出度和角膜暴露,改善容貌的目的。结果切除眶脂肪2.5～9.5ml,平均3.6ml,矫正眼球突出度2～6mm,平均3.0mm。提上睑肌延长5～10mm,平均7.6mm,矫正上睑退缩2.5～5mm,平均3.8mm。该治疗副作用少,不影响视力及眼球运动。结论眶脂肪切联合提上睑肌延长术可以缓解眼球突出和达到美容的效果,对保守治疗无效的甲状腺相关眼病是一种安全、有效,并发病少的治疗手段。     

Surgical Outcomes of Balanced Deep Lateral and Medial Orbital Wall Decompression in Korean Population: Clinical and Computed Tomography-based Analysis

PurposeTo evaluate the clinical outcomes of balanced deep lateral and medial orbital wall decompression and to estimate surgical effects using computed tomography (CT) images in Korean patients with thyroid-associated ophthalmopathy (TAO).MethodsRetrospective chart review was conducted in TAO patients with exophthalmos who underwent balanced deep lateral and medial orbital wall decompression. Exophthalmos was measured preoperatively and postoperatively at 1 and 3 months. Postoperative complications were evaluated in all study periods. In addition, decompressed bone volume was estimated using CT images. Thereafter, decompression volume in each decompressed orbital wall was analyzed to evaluate the surgical effect and predictability.ResultsTwenty-four patients (48 orbits) with an average age of 34.08 ± 7.03 years were evaluated. The mean preoperative and postoperative exophthalmos at 1 and 3 months was 18.91 ± 1.43, 15.10 ± 1.53, and 14.91 ± 1.49 mm, respectively. Bony decompression volume was 0.80 ± 0.29 cm³ at the medial wall and 0.68 ± 0.23 cm³ at the deep lateral wall. Postoperative complications included strabismus (one patient, 2.08%), upper eyelid fold change (four patients, 8.33%), and dysesthesia (four patients, 8.33%). Postsurgical exophthalmos reduction was more highly correlated with the deep lateral wall than the medial wall.ConclusionsIn TAO patients with exophthalmos, balanced deep lateral and medial orbital wall decompression is a good surgical method with a low-risk of complications. In addition, deep lateral wall decompression has higher surgical predictability than medial wall decompression, as seen with CT analysis.     

AdPLA基因在Ⅲ级静止期甲状腺相关眼病眼眶脂肪内高表达研究

目的 检测甲状腺相关眼病(thyroid associated ophthalmopathy,TAO)患者和正常人眼眶脂肪组织中脂肪特异性磷脂酶A2(adipose-specific phospholipase A2,AdPLA) mRNA的表达水平.方法 2015年8月至2016年10月16例静止期Ⅲ级TAO患者(TAO组)在深圳市眼科医院接受眼眶减压术,同期29位正常人(正常对照组)行眼部整形手术.术中取患者和正常对照一眼的眼眶脂肪;记录每位受试者的年龄、性别、身高、体质量,计算体质量指数(body mass index,BMI),测量取脂肪一侧眼的眼球突出度和眼眶脂肪体积;用实时定量多聚酶链式反应定量检测眼眶脂肪组织中AdPLA mRNA的表达水平.结果 TAO组与正常对照组年龄、性别和BMI相比差异均无统计学意义(均为P＞0.05),TAO组的眼球突出度(20.406±1.369)mm明显多于正常对照组(14.207±1.146) mm,TAO组的眼眶内脂肪量(32.162 ±1.923) mL明显多于正常对照组(24.279±1.070) mL.TAO组眼眶脂肪中AdPLA mRNA的表达量为0.039 42±0.009 85,正常对照组眼眶脂肪中AdPLA mRNA的表达量为0.004 42±0.001 36,两组相比差异有统计学意义(P＜0.05).结论 静止期Ⅲ级TAO患者的眼球突出度和眼眶内脂肪量明显多于正常人,眼眶脂肪组织中AdPLA mRNA的表达量明显高于正常人.AdPLA的高表达可能使TAO眼眶脂肪水解减少,造成眼眶脂肪堆积,加重了眼球突出.     

Balanced orbital decompression combined with fat removal in Graves ophthalmopathy: do we really need to remove the third wall?

PURPOSE: To compare the reduction of proptosis and the incidence of new-onset diplopia after 3-wall (medial, lateral, and inferior) orbital decompression versus balanced medial and lateral wall decompression combined with orbital fat excision in patients with Graves ophthalmopathy. METHODS: Three-wall orbital decompression including medial, inferior, and lateral walls was performed in 13 eyes of 7 patients (group 1), and balanced medial and lateral wall decompression combined with fat removal was performed in 18 eyes of 11 patients (group 2). A transnasal endoscopic approach was used for medial wall removal. A lateral canthotomy incision combined with a short upper eyelid incision was used for extended lateral wall removal, and this was combined with an inferior conjunctival fornix incision when floor decompression was performed. RESULTS: The mean reduction of proptosis was 6.9+/-1.6 mm and 6.5+/-1.3 mm in the first and second groups, respectively; the difference was not statistically significant (P=0.37). After 3-wall decompression, 57.1% of the patients had permanent new-onset diplopia (group 1), whereas none of the patients had permanent postoperative diplopia after balanced medial and lateral wall decompression combined with fat removal (group 2). The difference in permanent new-onset postoperative diplopia between two groups was statistically significant (P<0.001). CONCLUSIONS: Balanced medial and lateral wall decompression combined with orbital fat removal provides an effective reduction in proptosis and reduces the incidence of postoperative permanent diplopia when compared with 3-wall decompression. This technique may eliminate the need for orbital floor excision.     

Outcomes of Various Surgical Procedures on Acquired Lower Eyelid Epiblepharon in Thyroid Associated Ophthalmopathy

Purpose

To report the outcomes of acquired lower eyelid epiblepharon after various surgeries in thyroid associated ophthalmopathy (TAO) patients.

Methods

A retrospective review of the medical records of 53 TAO patients with acquired lower eyelid epiblepharon between October 1999 and June 2011 was performed. Data were collected on demographics, type of lower eyelid epiblepharon, the detailed surgical history such as orbital decompression, retraction repair, or epiblepharon repair and surgical outcomes including follow-up period, recurrence of epiblepharon, and post-operative complications.

Results

Among the 53 TAO patients with acquired lower eyelid epiblepharon, 25 eyes of 17 patients underwent surgical management; 6 eyes of orbital decompression, 1 eye of orbital decompression followed by retraction repair, 2 eyes of orbital decompression followed by epiblepharon repair, 6 eyes of lower eyelid retraction repair, and 10 eyes of epiblepharon repair. Twenty two lower eyelid epiblepharons (88%) were resolved after final surgical treatment without complication during mean 16.2 months (SD, ±29.9 months) of follow up period; three of 6 epiblepharons that remained after orbital decompression underwent subsequent surgical management of retraction repair or epiblepharon repair, and epiblepharons were well-corrected. Mean amount of lower eyelid retraction was decreased from 1.68 mm (SD, ±1.17 mm) to 0.29 mm (SD, ±0.44 mm) after surgery, regardless of the type of surgery (n = 25, p < 0.000, Wilcoxon signed rank test).

Conclusions

Acquired lower eyelid epiblepharon of TAO should be managed sequentially according to the general serial order of surgical managements in TAO; orbital decompression, correction of lower eyelid retraction and epiblepharon repair. Acquired lower eyelid epiblepharon was well resolved after surgical management in consecutive order, especially after repair of the lower eyelid retraction with a graft, or lower eyelid epiblepharon repair. Decreased lower eyelid retraction with a resolution of epiblepharon after surgery implied that lower eyelid retraction was associated with lower eyelid epiblepharon.     

深外侧壁联合内侧壁眼眶减压术治疗甲状腺相关性眼病

目的：探究深外侧壁联合内侧壁眼眶减压术治疗甲状腺相关性眼病的临床治疗效果及安全性。

方法：分析我科既往住院患者病历,纳入2019-01/2020-05在我科住院的符合纳入标准的甲状腺相关性眼病患者17例。所有患者均在全身麻醉下行深外侧壁联合内侧壁眼眶减压术,比较患者术前术后的视力、暴露性角膜炎恢复情况、突眼度、眼压以及并发症情况。

结果：所纳入研究的对象中,有甲状腺相关眼病视神经病变(DON)8例9眼,术前的最佳矫正视力0.78±0.15,术后1mo 0.36±0.12,与术前视力相比有差异(P<0.01),术后6mo 0.38±0.12,与术后1mo无差异(P=0.594)。术前眼球突出度23.75±2.55mm,术后1mo为14.85±1.53mm,与术前突眼度相比有差异(P<0.01),术后6mo为14.60±1.64mm,与术后1mo基本保持稳定(P=0.658)。术前眼压25.56±3.23mmHg,术后1mo为18.42±2.35mmHg,与术前相比有差异(P<0.01),术后6mo眼压降至15.82±2.57mmHg,与术后1mo眼压相比有差异(P<0.01)。术前有暴露性角膜炎6例6眼,术后1mo有4眼好转,2眼治愈,术后6mo 6眼全部治愈。术后患者复视情况均有不同程度减轻,并有部分患者复视症状在此后6mo持续好转,未出现其他严重并发症。

结论：深外侧壁联合内侧壁眼眶减压术可以有效地改善眼突,对DON及暴露性角膜炎等严重并发症也有良好的疗效,并发症少,是治疗严重甲状腺相关性眼病的有效手术方案。     

Results of transantral orbital decompression in patients with thyroid-associated ophthalmopathy

PURPOSE: To present the results of orbital decompression in patients with thyroid-associated ophthalmopathy (TAO). METHODS: Transantral orbital decompression was performed in 63 patients with TAO. In 40 patients (63%) the operation was made because of progressive ophthalmopathy not responding to medical therapy, and in 23 patients (37%) the operation was made for rehabilitative reasons. The long-term hypesthesia engaging the infraorbital nerve was assessed with a questionnaire using a Visual Analogue Scale (VAS). RESULTS: The mean proptosis reduction was 3.2 mm (range 0-8 mm). Twenty-one patients had impaired visual acuity preoperatively, and 20 improved. Altogether 30 patients (40%) had worsened ocular motility postoperatively. Forty-three patients did not have diplopia in the primary position preoperatively, and new diplopia developed in 22 of these (51%). Hypesthesia in the infraorbital nerve area was reported for half of the operated sides, but was a major cause of distress (VAS-scoring >5) to eleven patients. CONCLUSIONS: Transantral orbital decompression is indicated in patients with progressive TAO or in patients with prominent exophthalmos, and results in a good proptosis reduction, but the risk of postoperative diplopia is significant. Postoperative hypesthesia is common but often not a major problem.     

Characterization and Outcomes of Repeat Orbital Decompression for Thyroid-Associated Orbitopathy

Orbital decompression for thyroid-associated orbitopathy (TAO) is commonly performed for disfiguring proptosis, congestion, and optic neuropathy. Although one decompression typically achieves goals, a small percentage requires repeat decompression. We performed a 10-year retrospective chart review of all orbital decompressions for TAO at a single tertiary referral institution. Four-hundred and ninety-five orbits (330 patients) were decompressed for TAO, with 45 orbits (37 patients) requiring repeat decompression. We reviewed the repeat cases for indications, clinical activity scores, approach, walls decompressed, and outcomes. Nine percent of orbits required repeat decompression for proptosis (70%), optic neuropathy (25%) or congestion (45%). Sixty-four percent were for recurrence of disease, 36% were for suboptimal decompression. Three incisional approaches were used: lateral upper eyelid crease, inferior transconjunctival, and transcaruncular, with inferior transconjunctival being most common. Of the three walls removed, deep lateral, inferior, and medial, the deep lateral wall was most common (51%). A repeat lateral decompression was the most frequent pattern. Of 37 patients requiring repeat decompression, 40% had diplopia prior to repeat, and an additional 24% developed diplopia after the repeat. Whereas previous studies published by our group cited only 2.6% of deep lateral wall orbital decompressions leading to new-onset primary gaze diplopia, repeat orbital decompressions have a much higher rate of post-operative diplopia. The new onset primary gaze diplopia after repeat decompression group had a higher average preoperative CAS (3.3 vs. 2.4, p?p?=?0.04), more frequent medial wall decompressions (47% vs. 29%, p?=?0.33), and greater proptosis reduction (2.4 vs. 1.7?mm, p?=?0.24).     

Results and predictability of fat-removal orbital decompression for disfiguring graves exophthalmos in an Asian patient population

PURPOSE: To evaluate proptosis reduction by fat-removal orbital decompression (FROD), to determine the incidence of postoperative diplopia, and to assess predictability of proptosis reduction per volume of resected orbital fat. DESIGN: Cross-sectional study. METHODS: One hundred and twenty patients (31 men; 89 women) with Graves ophthalmopathy were treated with FROD via the transforniceal approach on 222 orbits between April 2003 and April 2006. Fifteen (12.5%) patients exhibited preoperative diplopia; 105 (87.5%) were without diplopia; mean follow-up +/- standard deviation (SD) was 10.9 +/- 5.1 months (range, six to 37 months). Univariate and multivariate analyses were used to evaluate Hertel change with FROD by linear regression. The setting was thyroid eye disease special clinics at National Taiwan University Hospital. RESULTS: Mean Hertel values +/- SD decreased from 20.3 +/- 1.8 mm (range, 16.5 to 26.0 mm) to 16.8 +/- 1.4 mm (range, 13.5 to 21.0). Mean proptosis reduction +/- SD was 3.6 +/- 1.0 mm (range, 1.5 to 7.5 mm). Mean volume of resected orbital fat +/- SD was 3.6 +/- 1.0 ml (range, 1.2 to 6.5 ml). New-onset diplopia was noted for 2.8% of patients after FROD. The final predictive equation for Hertel change is shown as: 0.72 x removal of intraconal fat (ml) - 0.001 x age (yrs) - 0.22 x gender (male, 1; female, 0) - 0.19 x preoperative diplopia (yes, 1; no, 0) + 1.02. CONCLUSIONS: FROD can achieve reasonable proptosis reduction and can reduce incidence of new-onset diplopia for patients with disfiguring Graves exophthalmos. The volume of resected orbital fat correlates with mean Hertel value change. The amount of resected orbital fat may predict proptosis reduction.